Early effect of the HPV vaccination programme on cervi Australia: an ecological study

Lancet, The

377, 2085-2092

DOI: 10.1016/s0140-6736(11)60551-5

Citation Report

#	Article	IF	Citations
1	Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact. Expert Review of Anti-Infective Therapy, 2011, 9, 627-639.	2.0	15
3	The global burden of disease in 10â€“24-year-olds. Lancet, The, 2011, 377, 2058-2060.	6.3	8
4	HPV vaccine effect: is the glass half full or half empty?. Lancet, The, 2011, 377, 2057-2058.	6.3	3
5	HPV Vaccine Reduces Cervical Abnormalities in Teens. American Journal of Nursing, 2011, 111, 16.	0.2	0
6	Dominant role of HPV16 E7 in anal carcinogenesis. Virology, 2011, 421, 114-118.	1.1	34
7	Adolescent and young adult HPV vaccination in Australia: Achievements and challenges. Preventive Medicine, 2011, 53, S29-S35.	1.6	69
8	Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Preventive Medicine, 2011, 53, S12-S21.	1.6	201
9	The human papillomavirus (HPV) vaccine and cervical cancer: Uptake and next steps. Advances in Therapy, 2011, 28, 615-639.	1.3	32
10	Human papillomavirus infections in the oral mucosa. Journal of the American Dental Association, 2011, 142, 905-914.	0.7	81
11	Cervical Cancer Prevention: Better Tests, Better Tools, and More Equitable Outcomes. Journal of the National Cancer Institute, 2011, 103, 1352-1353.	3.0	6
12	The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sexually Transmitted Infections, 2011, 87, 544-547.	0.8	220
14	Human papillomavirus testing: the challenges of picking the right tools for the job. Expert Review of Obstetrics and Gynecology, 2011, 6, 643-653.	0.4	5
15	Human papillomavirus vaccination: where to now?. Sexually Transmitted Infections, 2011, 87, ii23-ii24.	0.8	2
16	Population benefits of HPV vaccination for boys: a complex equation. Evidence-Based Medicine, 2012, 17, 118-119.	0.6	0
17	Monitoring HPV Vaccine Impact: Early Results and Ongoing Challenges. Journal of Infectious Diseases, 2012, 206, 1633-1635.	1.9	3
18	Vaccination against sexually transmitted infections. Current Opinion in Infectious Diseases, 2012, 25, 66-72.	1.3	17
20	Vaccination and herd immunity. Current Opinion in Infectious Diseases, 2012, 25, 243-249.	1.3	98
21	Cervical cancer in the human papillomavirus vaccination era. Current Opinion in Obstetrics and Gynecology, 2012, 24, 3-7.	0.9	23

#	Article	IF	Citations
22	Cervical Cancer Burden and Prevention Strategies: Asia Oceania Perspective. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1414-1422.	1.1	23
23	Managing Sexually Transmitted Infections in Pregnant Women. Women's Health, 2012, 8, 313-321.	0.7	9
24	Cervical Cancer Screening in the United States, 1993â€“2010: Characteristics of Women Who Are Never Screened. Journal of Women's Health, 2012, 21, 1132-1138.	1.5	51
25	The value of HPV vaccination. Nature Medicine, 2012, 18, 28-29.	15.2	5
26	Fall in Human Papillomavirus Prevalence Following a National Vaccination Program. Journal of Infectious Diseases, 2012, 206, 1645-1651.	1.9	218
27	Clinical approval: Trials of an anticancer jab. Nature, 2012, 488, S4-S6.	13.7	5
29	Pap Tests Every 3â€“5 Years. Obstetrics and Gynecology, 2012, 120, 9-11.	1.2	4
30	Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges. Clinical Microbiology and Infection, 2012, 18, 64-69.	2.8	17
31	Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, The, 2012, 13, 89-99.	5.1	584
32	Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. Journal of Infection and Chemotherapy, 2012, 18, 807-815.	0.8	128
33	Human papillomavirus, lichen sclerosus and penile cancer: A study in Belgium. Vaccine, 2012, 30, 6573-6577.	1.7	33
34	Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine, 2012, 31, 109-113.	1.7	74
37	Controlling measles in NSW: how are we doing in the context of other countries in the Western Pacific?. NSW Public Health Bulletin, 2012, 23, 169.	0.3	0
38	Genital warts are more than an inconvenience!. Public Health, 2012, 126, 546-547.	1.4	1
39	Interest in having HPV vaccination among adolescent boys in England. Vaccine, 2012, 30, 4505-4510.	1.7	29
40	High HPV vaccination uptake rates for adolescent girls after regional governmental funding in Shiki City, Japan. Vaccine, 2012, 30, 5547-5550.	1.7	18
41	Vaccination to protect against infection of the female reproductive tract. Expert Review of Clinical Immunology, 2012, 8, 81-94.	1.3	14
42	Cervical screening: primary human papillomavirus testing. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 650-652.	1.1	1

#	Article	IF	Citations
44	Expenditure and resource utilisation for cervical screening in Australia. BMC Health Services Research, 2012, 12, 446.	0.9	18
45	Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nature Reviews Microbiology, 2012, 10, 681-692.	13.6	199
46	Human Papillomavirus Vaccine Introduction â€“ The First Five Years. Vaccine, 2012, 30, F139-F148.	1.7	260
47	A human papillomavirus public vaccination program in Taiwan: The Kinmen County experience. Journal of the Formosan Medical Association, 2012, 111, 682-685.	0.8	9
48	HPV Vaccination and Cervical Cancer. Current Oncology Reports, 2012, 14, 559-567.	1.8	10
49	Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries. Vaccine, 2012, 30, F157-F167.	1.7	97
50	Human Papillomavirus Vaccines: Where Do They Fit in HIV-Infected Individuals?. Current HIV/AIDS Reports, 2012, 9, 278-286.	1.1	14
51	Human Papillomavirus Vaccines â€“ Immune Responses. Vaccine, 2012, 30, F83-F87.	1.7	136
52	Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Economics Review, 2012, 2, 19.	0.8	20
53	Tracking type specific prevalence of human Papillomavirus in cervical pre-cancer: a novel sampling strategy. BMC Medical Research Methodology, 2012, 12, 77.	1.4	0
54	Major clinical research advances in gynecologic cancer in 2011. Journal of Gynecologic Oncology, 2012, 23, 53.	1.0	34
55	Immunogenicity, Efficacy, Effectiveness and Overall Impact of HPV Vaccines. , 2012, , 257-272.		1
56	EUROGIN 2011 roadmap on prevention and treatment of HPVâ€related disease. International Journal of Cancer, 2012, 131, 1969-1982.	2.3	204
57	Prophylactic human papillomavirus vaccines: past, present and future. Pathology, 2012, 44, 1-6.	0.3	14
58	HEADS UP. Journal of Paediatrics and Child Health, 2012, 48, 75-76.	0.4	0
59	Type 1 and type 2 cervical carcinomas: some cervical cancers are more difficult to prevent with screening. Cytopathology, 2012, 23, 6-12.	0.4	16
60	Mise au point sur les recommandations franÃ§aises de la vaccination contre les infections Ã papillomavirus. Journal Des Anti-infectieux, 2012, 14, 42-49.	0.1	1
61	Is this really an ethical evaluation of HPV vaccination policy in Australia?. Australian and New Zealand Journal of Public Health, 2012, 36, 96.	0.8	1

#	Article	IF	Citations
62	Avis du Haut Conseil de la santÃ© publique relatif au vaccin GardasilÂ® et Ã la stratÃ©gie de prÃ©vention globale des cancers du col de lâ€™utÃ©rus. Journal De Pediatrie Et De Puericulture, 2012, 25, 48-53.	0.0	0
63	HEADS UP. Journal of Paediatrics and Child Health, 2012, 48, 182-183.	0.4	0
65	Cervical Adenocarcinoma in Situ: Update and Management. Current Obstetrics and Gynecology Reports, 2013, 2, 86-93.	0.3	6
67	Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infectious Diseases, 2013, 13, 140.	1.3	81
68	Challenges in Cervical Cancer Prevention. American Journal of Preventive Medicine, 2013, 45, 175-181.	1.6	73
69	Human Papillomavirus-Associated Diseases in Israel â€“ The Controversy Continues. Vaccine, 2013, 31, vii-x.	1.7	4
70	Parental and societal support for adolescent immunization through school based immunization programs. Vaccine, 2013, 31, 3059-3064.	1.7	11
71	Breast and Gynecological Cancers. , 2013, , .		7
73	Population Impact of HPV Vaccines: Summary of Early Evidence. Journal of Adolescent Health, 2013, 53, 679-682.	1.2	63
74	Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment. American Journal of Epidemiology, 2013, 178, 752-760.	1.6	26
75	Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study). BMC Cancer, 2013, 13, 296.	1.1	20
76	Towards the eradication of HPV infection through universal specific vaccination. BMC Public Health, 2013, 13, 642.	1.2	41
77	Uptake of liquid-based cytology as an adjunct to conventional cytology for cervical screening in NSW, Australia: a cross-sectional and population-based cohort analysis. BMC Public Health, 2013, 13, 1196.	1.2	1
78	Health at a Glance 2013. Health at A Glance: OECD Indicators, 2013, , .	1.0	390
79	Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United Statesâ€”Do we need a broader vaccine policy?. Vaccine, 2013, 31, 5500-5505.	1.7	43
80	Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Vaccine, 2013, 31, 3962-3971.	1.7	21
81	Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. Vaccine, 2013, 31, 3899-3905.	1.7	10
82	Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (<scp>GARDASIL</scp>) in <scp>J</scp>apanese women aged 18â€“26Âyears. Cancer Science, 2013, 104, 465-472.	1.7	34

#	Article	IF	Citations
83	Could Alarmingly High Rates of Negative Diagnoses in Remote Rural Areas Be Minimized with Liquid-Based Cytology? Preliminary Results from the RODEO Study Team. Acta Cytologica, 2013, 57, 69-74.	0.7	8
84	Clinical trials of human papillomavirus vaccines and beyond. Nature Reviews Clinical Oncology, 2013, 10, 400-410.	12.5	147
85	Vaccination and Screening in Cervical Cancer Control and Prevention. , 2013, , 1175-1189.		0
86	Human Papillomavirus Vaccination. Obstetrics and Gynecology Clinics of North America, 2013, 40, 177-197.	0.7	18
87	Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ, The, 2013, 346, f2032-f2032.	3.0	363
88	Changes in Incidence of Anogenital Warts Diagnoses After the Introduction of Human Papillomavirus Vaccination in Germanyâ€"An Ecologic Study. Sexually Transmitted Diseases, 2013, 40, 28-31.	0.8	35
89	Effects on Cervical Cytology Screening Productivity Associated with Implementation of the BD FocalPointÂ™ Guided Screener Imaging System. Acta Cytologica, 2013, 57, 147-152.	0.7	5
90	Declining Rates of High-Grade Cervical Lesions in Young Women in Connecticut, 2008â€"2011. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1446-1450.	1.1	53
92	Attitudes Toward HPV Vaccination Among Low-Income and Minority Parents of Sons. Clinical Pediatrics, 2013, 52, 231-240.	0.4	32
95	Why the time is right to tackle breast and cervical cancer in low-resource settings. Bulletin of the World Health Organization, 2013, 91, 683-690.	1.5	61
96	Human Papillomavirus Vaccination for the Prevention of Cervical and Other Related Cancers. Statistics in the Health Sciences, 2013, , 45-64.	0.2	2
97	Response. Journal of the National Cancer Institute, 2013, 105, 664-665.	3.0	1
98	RE: Population-Level Impact of the Bivalent, Quadrivalent, and Candidate Nonavalent Human Papillomavirus Vaccines: A Comparative Model-Based Analysis. Journal of the National Cancer Institute, 2013, 105, 664-664.	3.0	2
99	Re: Nonsteroidal Anti-inflammatory Drug Use, Chronic Liver Disease, and Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2013, 105, 665-666.	3.0	6
100	Incidence of potentially human papillomavirusâ€"related neoplasms in the United States, 1978 to 2007. Cancer, 2013, 119, 2291-2299.	2.0	48
101	Individual and geographic disparities in human papillomavirus types 16/18 in highâ€grade cervical lesions. Cancer, 2013, 119, 3052-3058.	2.0	44
102	Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Medicine, 2013, 11, 227.	2.3	232
103	Prevalence and Distribution of Human Papillomavirus Genotype in South Eastern Italy, in the Period 2006-2011: Implications for Intervention. Current Pharmaceutical Design, 2013, 19, 1498-1507.	0.9	2

#	Article	IF	Citations
104	Evaluating Human Papillomavirus Vaccination Programs. Sexually Transmitted Diseases, 2013, 40, 290-291.	0.8	3
105	Factors Affecting Human Papillomavirus Vaccine Use Among White, Black and Latino Parents of Sons. Pediatric Infectious Disease Journal, 2013, 32, e38-e44.	1.1	47
106	Safety and Immunogenicity of a Hexavalent Vaccine Administered at 2, 4 and 6 Months of Age With or Without a Heptavalent Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2013, 32, 54-61.	1.1	23
107	The high burden of cervical cancer in Fiji, 2004â€“07. Sexual Health, 2013, 10, 171.	0.4	10
108	Human papillomavirus vaccine coverage among female Australian adolescents: success of the schoolâ€based approach. Medical Journal of Australia, 2013, 199, 614-617.	0.8	102
110	Human Papillomavirus Type 6 and 11 Genetic Variants Found in 71 Oral and Anogenital Epithelial Samples from Australia. PLoS ONE, 2013, 8, e63892.	1.1	23
111	Human Papillomavirus Types Distribution in Organised Cervical Cancer Screening in France. PLoS ONE, 2013, 8, e79372.	1.1	30
112	HPV Diagnosis in Vaccination Era. , 2013, , .		0
113	Acceptability and Correlates of Primary and Secondary Prevention of Cervical Cancer among Medical Students in Southwest China: Implications for Cancer Education. PLoS ONE, 2014, 9, e110353.	1.1	26
114	The Road Ahead for Cervical Cancer Prevention and Control. Current Oncology, 2014, 21, 255-264.	0.9	41
115	Cervical cancer: Can it be prevented?. World Journal of Clinical Oncology, 2014, 5, 775.	0.9	55
117	Factors impacting HPV vaccination: lessons for health care professionals. Expert Review of Vaccines, 2014, 13, 1013-1026.	2.0	35
120	Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. British Journal of Cancer, 2014, 110, 2804-2811.	2.9	157
121	Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. British Journal of Cancer, 2014, 111, 1824-1830.	2.9	146
122	Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. Journal of the National Cancer Institute, 2014, 107, dju400-dju400.	3.0	24
123	The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Review of Vaccines, 2014, 13, 1279-1290.	2.0	71
125	Veracity and rhetoric in paediatric medicine: a critique of Svoboda and Van Howe's response to the AAP policy on infant male circumcision. Journal of Medical Ethics, 2014, 40, 463-470.	1.0	22
126	Impact of HPV immunization on the detection of cervical disease. Expert Review of Vaccines, 2014, 13, 533-544.	2.0	0

#	Article	IF	Citations
127	AAV Vectors Vaccines Against Infectious Diseases. Frontiers in Immunology, 2014, 5, 5.	2.2	83
128	Web-based Recruiting for a Survey on Knowledge and Awareness of Cervical Cancer Prevention Among Young Women Living in Kanagawa Prefecture, Japan. International Journal of Gynecological Cancer, 2014, 24, 1347-1355.	1.2	25
129	Lessons Learned From HPV Vaccine Delivery in Low-Resource Settings and Opportunities for HIV Prevention, Treatment, and Care Among Adolescents. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, S209-S216.	0.9	15
130	The use of supplementary immunisation activities to improve uptake of current and future vaccines in low-income and middle-income countries: a systematic review protocol. BMJ Open, 2014, 4, e004429.	0.8	10
131	Prevention of HPV Disease Burden. Women's Health, 2014, 10, 341-343.	0.7	0
132	Global evidence reaffirms the case for routine HPV and potential HIV adolescent vaccination in South Africa. Future Virology, 2014, 9, 207-220.	0.9	2
133	Benefits and Risks of Cervical Cancer Screening. Oncology Research and Treatment, 2014, 37, 48-57.	0.8	19
134	Attitudes toward cervical cancer screening among women receiving human papillomavirus vaccination in a universityâ€hospitalâ€based community: Interim 2â€year followâ€up results. Journal of Obstetrics and Gynaecology Research, 2014, 40, 1105-1113.	0.6	5
135	HPV and cervical cancer. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 59-62.	0.6	56
136	Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination. Current Opinion in Oncology, 2014, 26, 120-129.	1.1	13
137	Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia--Nationwide Follow-up of Young Danish Women. Journal of the National Cancer Institute, 2014, 106, djt460-djt460.	3.0	155
138	Monitoring the Impact of a National HPV Vaccination Program in Japan (MINT Study): Rationale, Design and Methods. Japanese Journal of Clinical Oncology, 2014, 44, 1000-1003.	0.6	12
139	HPV vaccines in Brazil and the world. BMC Proceedings, 2014, 8, .	1.8	3
140	The Future Role for Colposcopy in Europe. Journal of Lower Genital Tract Disease, 2014, 18, 70-78.	0.9	13
141	Virus Infection and Human Cancer: An Overview. Recent Results in Cancer Research, 2014, 193, 1-10.	1.8	62
142	Assessing the need for and acceptability of a free-of-charge postpartum HPV vaccination program. American Journal of Obstetrics and Gynecology, 2014, 210, 213.e1-213.e7.	0.7	9
143	Prophylactic papillomavirus vaccines. Clinics in Dermatology, 2014, 32, 235-247.	0.8	19
144	Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine, 2014, 32, 733-739.	1.7	49

#	Article	IF	Citations
145	Prevalence and risk factors of human papillomavirus infection types 16/18/45 in a cohort of French females aged 15â€“23 years. Journal of Epidemiology and Global Health, 2014, 4, 35.	1.1	15
146	The Australian Experience With the Human Papillomavirus Vaccine. Clinical Therapeutics, 2014, 36, 17-23.	1.1	73
147	Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes and Control, 2014, 25, 915-922.	0.8	66
148	Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer. Expert Opinion on Biological Therapy, 2014, 14, 527-534.	1.4	5
149	Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infectious Diseases, The, 2014, 14, 958-966.	4.6	243
150	Long-term Study of a Quadrivalent Human Papillomavirus Vaccine. Pediatrics, 2014, 134, e657-e665.	1.0	93
151	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet, The, 2014, 384, 2213-2227.	6.3	153
152	Effectiveness of the Quadrivalent Human Papillomavirus Vaccine Against Cervical Dysplasia in Manitoba, Canada. Journal of Clinical Oncology, 2014, 32, 438-443.	0.8	40
153	Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GardasilÂ®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts. Drugs, 2014, 74, 1253-1283.	4.9	56
154	Practices and opinions regarding HPV vaccination among French general practitioners: evaluation through two cross-sectional studies in 2007 and 2010. International Journal of Public Health, 2014, 59, 519-528.	1.0	13
155	Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine, 2014, 32, 759-765.	1.7	16
156	Testing previous model predictions against new data on human papillomavirus vaccination program outcomes. BMC Research Notes, 2014, 7, 109.	0.6	14
157	Early Acquisition of Anogenital Human Papillomavirus Among Teenage Men Who Have Sex With Men. Journal of Infectious Diseases, 2014, 209, 642-651.	1.9	57
158	Advances in colposcopy: new technologies to challenge current practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 182, 140-145.	0.5	7
159	Papillomavirus vaccination in France according to 2008 to 2012 VaccinoscopieÂ® data. MÃ©decine Et Maladies Infectieuses, 2014, 44, 18-24.	5.1	10
160	Human papillomavirus vaccination: Where are we now?. Journal of Paediatrics and Child Health, 2014, 50, 959-965.	0.4	20
161	Adolescent Girlsâ€™ Preferences for HPV Vaccines: A Discrete Choice Experiment. Advances in Health Economics and Health Services Research, 2014, , 93-121.	0.2	22
162	System dynamics model of cervical cancer vaccination and screening interventions in Kenya. Cost Effectiveness and Resource Allocation, 2014, 12, 26.	0.6	7

#	Article	IF	Citations
163	Vulval cancer and HPV vaccination in recurrent disease. Clinical Case Reports (discontinued), 2014, 2, 243-246.	0.2	5
164	Can the HPV vaccine prevent more than cervical cancer? An epidemiologic perspective. Future Virology, 2014, 9, 887-889.	0.9	0
165	An Overview of Quadrivalent Human Papillomavirus Vaccine Safety. Pediatric Infectious Disease Journal, 2015, 34, 983-991.	1.1	103
166	No change in physician discussions with patients about the human papillomavirus vaccine between 2007 and 2013. Journal of Cancer Policy, 2015, 5, 18-22.	0.6	2
167	Human papillomavirus knowledge, vaccine acceptance, and vaccine series completion among female entertainment and sex workers in Phnom Penh, Cambodia: the Young Womenâ€™s Health Study. International Journal of STD and AIDS, 2015, 26, 893-902.	0.5	19
168	Estimation of Cancer Burden Attributable to Infection in Asia. Journal of Epidemiology, 2015, 25, 626-638.	1.1	18
169	Evaluation of p16INK4a immunostaining for the detection of high-grade changes in cervical cytology. Pathology, 2015, 47, 314-319.	0.3	3
170	HPV9 Vaccine for the Prevention of Human Papillomavirusâ€“Related Cancers. Nursing for Women's Health, 2015, 19, 365-370.	0.3	2
171	Reduction in cervical intraepithelial neoplasia in young women in <scp>B</scp>ritish <scp>C</scp>olumbia after introduction of the <scp>HPV</scp> vaccine: An ecological analysis. International Journal of Cancer, 2015, 137, 1931-1937.	2.3	33
172	Current status of human papillomavirus vaccination. Current Opinion in Oncology, 2015, 27, 399-404.	1.1	28
173	Bethesda 2014: improving on a paradigm shift. Cytopathology, 2015, 26, 339-342.	0.4	31
174	An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11â€“15 Years of Age. Pediatric Infectious Disease Journal, 2015, 34, 627-634.	1.1	31
175	Chlamydia trachomatis Co-infection in HPV Positive Women brings no Additional Risk of High-grade Cervical Intraepithelial Neoplasia. Journal of Cytology & Histology, 2015, s3, .	0.1	0
176	Current and Next-generation Vaccines against Human Papillomaviruses. Journal of Bacteriology and Virology, 2015, 45, 189.	0.0	0
177	Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. Journal of Clinical Medicine, 2015, 4, 614-633.	1.0	78
178	From the monovalent to the nine-valent HPV vaccine. Clinical Microbiology and Infection, 2015, 21, 827-833.	2.8	57
180	Novel Approaches for Vaccination Against HPV-Induced Cancers. Current Topics in Microbiology and Immunology, 2015, 405, 33-53.	0.7	1
181	A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus GardasilÂ® in 9â€“15-Year-Old Girls. Pediatric Infectious Disease Journal, 2015, 34, 992-998.	1.1	89

#	Article	IF	Citations
182	Skin and Mucosal Human Papillomavirus Seroprevalence in Persons with Fanconi Anemia. Vaccine Journal, 2015, 22, 413-420.	3.2	12
183	Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions. BMJ Open, 2015, 5, e008439.	0.8	19
184	Foundations of Biomedical Knowledge Representation. Lecture Notes in Computer Science, 2015, , .	1.0	4
185	Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. Vaccine, 2015, 33, 1284-1290.	1.7	40
186	Effectiveness of a provider-focused intervention to improve HPV vaccination rates in boys and girls. Vaccine, 2015, 33, 1223-1229.	1.7	122
187	HPV genotyping for triage of women with abnormal cervical cancer screening results: a multicenter prospective study. International Journal of Clinical Oncology, 2015, 20, 974-981.	1.0	15
188	A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. New England Journal of Medicine, 2015, 372, 711-723.	13.9	1,090
189	Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (GardasilÂ®): a guide to its use in the EU. Drugs and Therapy Perspectives, 2015, 31, 1-8.	0.3	2
190	Human papilloma virus vaccination: impact and recommendations across the world. Therapeutic Advances in Vaccines, 2015, 3, 3-12.	2.7	52
191	Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 90-100.	4.5	78
192	Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics, 2015, 136, e28-e39.	1.0	105
193	HPV vaccination crisis in Japan. Lancet, The, 2015, 385, 2571.	6.3	266
194	Menopause and Cancers. Endocrinology and Metabolism Clinics of North America, 2015, 44, 603-617.	1.2	9
195	Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine, 2015, 33, 6892-6901.	1.7	104
196	Present status of human papillomavirus vaccine development and implementation. Lancet Oncology, The, 2015, 16, e206-e216.	5.1	165
197	Next generation prophylactic human papillomavirus vaccines. Lancet Oncology, The, 2015, 16, e217-e225.	5.1	110
198	Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. Cancer Causes and Control, 2015, 26, 953-954.	0.8	42
199	The Next Steps in Cervical Screening. Women's Health, 2015, 11, 201-212.	0.7	11

#	Article	IF	Citations
200	Monitoring the impact of human papillomavirus vaccines on high-grade pre-invasive cervical lesions: Designing a framework of linked immunization information system and cancer registry data in Michigan. Vaccine, 2015, 33, 1400-1405.	1.7	7
201	Cervical Cancer Prevention. Medical Clinics of North America, 2015, 99, 469-477.	1.1	30
202	Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemporary Clinical Trials, 2015, 42, 18-25.	0.8	19
203	Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2015, 15, 565-580.	4.6	556
204	9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Expert Review of Vaccines, 2015, 14, 1405-1419.	2.0	38
205	The impact of HPV vaccination on future cervical screening: a simulation study of two birth cohorts in Denmark. BMJ Open, 2015, 5, e007921.	0.8	15
206	Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infectious Diseases, The, 2015, 15, 1314-1323.	4.6	56
207	Disparities in Human Papillomavirus Vaccine Literacy and Vaccine Completion Among Asian American Pacific Islander Undergraduates: Implications for Cancer Health Equity. Journal of American College Health, 2015, 63, 316-323.	0.8	45
208	A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing. Journal of Clinical Virology, 2015, 69, 210-213.	1.6	16
209	An update on barriers to adolescent human papillomavirus vaccination in the USA. Expert Review of Vaccines, 2015, 14, 1377-1384.	2.0	17
210	Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26Âyears of age in Sub-Saharan Africa. Human Vaccines and Immunotherapeutics, 2015, 11, 1323-1330.	1.4	18
211	European Code against Cancer 4th Edition: Infections and Cancer. Cancer Epidemiology, 2015, 39, S120-S138.	0.8	34
212	HPV prophylactic vaccines: lessons learned from 10 years experience. Future Virology, 2015, 10, 999-1009.	0.9	7
213	Site-specific human papillomavirus infection in adolescent men who have sex with men (HYPER): an observational cohort study. Lancet Infectious Diseases, The, 2015, 15, 65-73.	4.6	40
215	How adolescent <scp>J</scp>apanese girls arrive at human papilloma virus vaccination: A semistructured interview study. Australian Journal of Cancer Nursing, 2015, 17, 15-25.	0.8	5
216	Fall in Genital Warts Diagnoses in the General and Indigenous Australian Population Following Implementation of a National Human Papillomavirus Vaccination Program: Analysis of Routinely Collected National Hospital Data. Journal of Infectious Diseases, 2015, 211, 91-99.	1.9	71
217	<scp>E</scp>UROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirusâ€related cancer incidence by gender and anatomic site of infection. International Journal of Cancer, 2015, 136, 2752-2760.	2.3	243
218	Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. Expert Review of Vaccines, 2015, 14, 119-133.	2.0	11

#	Article	IF	Citations
219	Papillomavirus. , 2016, , 625-678.		0
220	Ten years of anti-HPV vaccinations: what do we know?. Przeglad Menopauzalny, 2016, 3, 170-175.	0.6	7
221	Using the Cancer Risk Management Model to Evaluate the Health and Economic Impacts of Cytology Compared with Human Papillomavirus DNA Testing for Primary Cervical Cancer Screening in Canada. Current Oncology, 2016, 23, 56-63.	0.9	10
222	Cervical cancer screening in Belgium and overscreening of adolescents. European Journal of Cancer Prevention, 2016, 25, 142-148.	0.6	29
223	Practice Bulletin No. 157. Obstetrics and Gynecology, 2016, 127, e1-e20.	1.2	99
224	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infectious Diseases, The, 2016, 16, 1154-1168.	4.6	148
225	Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. Cmaj, 2016, 188, E281-E288.	0.9	34
226	ACOG. Obstetrics and Gynecology, 2016, 128, e111-e130.	1.2	175
227	Results of a Multilevel Intervention Trial to Increase Human Papillomavirus (HPV) Vaccine Uptake among Adolescent Girls. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 593-602.	1.1	47
228	Impact of school-entry and education mandates by states on HPV vaccination coverage: Analysis of the 2009â€“2013 National Immunization Survey-Teen. Human Vaccines and Immunotherapeutics, 2016, 12, 1615-1622.	1.4	41
229	Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females. JAMA Pediatrics, 2016, 170, 445.	3.3	26
231	Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community. Clinical Infectious Diseases, 2016, 63, 1281-1287.	2.9	44
232	Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. Ca-A Cancer Journal for Clinicians, 2016, 66, 375-385.	157.7	60
233	New Vaccines on the Horizon. Current Pediatrics Reports, 2016, 4, 74-83.	1.7	0
234	Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria. BMC Public Health, 2016, 16, 889.	1.2	8
235	Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12â€“15Âyears: Interim analysis of a large community-randomized controlled trial. Human Vaccines and Immunotherapeutics, 2016, 12, 3177-3185.	1.4	24
236	Ecological Association of Human Papillomavirus Vaccination with Cervical Dysplasia Prevalence in the United States, 2007â€“2014. American Journal of Public Health, 2016, 106, 2211-2218.	1.5	41
237	Trends in Colposcopy Volume: Where Do We Go From Here?. Journal of Lower Genital Tract Disease, 2016, 20, 292-295.	0.9	9

#	Article	IF	Citations
238	Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study. BMC Public Health, 2016, 16, 1223.	1.2	34
240	Monitoring the impact of HPV vaccine in malesâ€"Considerations and challenges. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 106-111.	4.5	20
241	Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. Human Vaccines and Immunotherapeutics, 2016, 12, 30-38.	1.4	31
242	Clinicians' attitude towards changes in Australian National Cervical Screening Program. Journal of Clinical Virology, 2016, 76, S81-S87.	1.6	10
243	Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. Journal of Clinical Virology, 2016, 76, S62-S68.	1.6	72
244	Cervical cancer prevention in Australia: Planning for the future. Cancer Cytopathology, 2016, 124, 235-240.	1.4	18
245	Surveillance of effects of HPV vaccination in Belgium. Cancer Epidemiology, 2016, 41, 152-158.	0.8	20
246	Interventions to increase HPV vaccination coverage: A systematic review. Human Vaccines and Immunotherapeutics, 2016, 12, 1566-1588.	1.4	125
248	Estimating human papillomavirus vaccination coverage among young women in Victoria and reasons for non-vaccination. Sexual Health, 2016, 13, 190.	0.4	5
249	Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. Human Vaccines and Immunotherapeutics, 2016, 12, 1332-1342.	1.4	29
250	Human papillomavirus molecular biology. Mutation Research - Reviews in Mutation Research, 2017, 772, 3-12.	2.4	146
251	The impact of human papillomavirus type on colposcopy performance in women offered <scp>HPV</scp> immunisation in a catchâ€up vaccine programme: a twoâ€centre observational study. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 1394-1401.	1.1	15
252	Realizing the Potential of Cancer Prevention â€" The Role of Implementation Science. New England Journal of Medicine, 2017, 376, 986-990.	13.9	90
253	Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. Preventive Medicine, 2017, 98, 5-14.	1.6	87
254	Radiofrequency electromagnetic fields and some cancers of unknown etiology: An ecological study. Science of the Total Environment, 2017, 599-600, 834-843.	3.9	24
257	HPV vaccines â€“ A review of the first decade. Gynecologic Oncology, 2017, 146, 196-204.	0.6	304
258	Declines in Human Papillomavirus (HPV)â€"Associated High-Grade Cervical Lesions After Introduction of HPV Vaccines in Connecticut, United States, 2008â€"2015. Clinical Infectious Diseases, 2017, 65, 884-889.	2.9	24
259	Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents. Sexually Transmitted Diseases, 2017, 44, 365-370.	0.8	20

#	Article	IF	Citations
260	Cervical Screening: History, Current Algorithms, and Future Directions. , 2017, , 45-65.		2
261	Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infectious Diseases, The, 2017, 17, 1293-1302.	4.6	186
262	Missed Opportunities for Human Papillomavirus Vaccine Initiation in an Insured Adolescent Female Population. Journal of the Pediatric Infectious Diseases Society, 2017, 6, 360-365.	0.6	8
263	Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination. International Journal of Cancer, 2017, 141, 1576-1584.	2.3	51
264	Overcoming barriers in HPV vaccination and screening programs. Papillomavirus Research (Amsterdam, Netherlands), 2017, 4, 45-53.	4.5	41
265	Human Papilloma Virus Vaccination and Incidence of Ocular Surface Squamous Neoplasia. International Ophthalmology Clinics, 2017, 57, 57-74.	0.3	7
266	The Power and Pitfalls of Big Data Research in Obstetrics and Gynecology: A Consumer's Guide. Obstetrical and Gynecological Survey, 2017, 72, 669-682.	0.2	11
267	Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine. Human Vaccines and Immunotherapeutics, 2017, 13, 2280-2291.	1.4	19
268	Maximizing the Impact of Human Papillomavirus Vaccination. Clinical Infectious Diseases, 2017, 65, 890-892.	2.9	0
269	Health-related quality of life as measured by the EQ-5D in the prevention, screening and management of cervical disease: A systematic review. Quality of Life Research, 2017, 26, 2885-2897.	1.5	7
271	Diverse Familiesâ€™ Experiences with HPV Vaccine Information Sources: A Community-Based Participatory Approach. Journal of Community Health, 2017, 42, 400-412.	1.9	29
272	Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus. Journal of the National Cancer Institute, 2017, 109, djw216.	3.0	72
273	Human Papillomavirus Infections. , 2017, , 575-584.e1.		0
274	Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination. Advances in Clinical Chemistry, 2017, 81, 135-192.	1.8	13
276	Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data. Medical Journal of Australia, 2017, 206, 204-209.	0.8	33
277	Dr. Bibbo's Presidential Address on Automation in Cytology: Were Her Predictions Right, Wrong, or Somewhere in the Middle?. Acta Cytologica, 2017, 61, 345-358.	0.7	5
278	Human papillomavirus vaccination: the population impact. F1000Research, 2017, 6, 866.	0.8	73
279	What information can change the attitude of teachers toward the human papillomavirus vaccine?. Journal of Obstetrics and Gynaecology Research, 2018, 44, 778-787.	0.6	3

#	Article	IF	Citations
280	A Qualitative Comparative Analysis of Combined State Health Policies Related to Human Papillomavirus Vaccine Uptake in the United States. American Journal of Public Health, 2018, 108, 493-499.	1.5	23
281	Strengthening the case for gender-neutral and the nonavalent HPV vaccine. European Archives of Oto-Rhino-Laryngology, 2018, 275, 857-865.	0.8	10
282	Juvenile-Onset Recurrent Respiratory Papillomatosis: The Benefits of Quadrivalent Human Papillomavirus Vaccination Continue to Accrue. Journal of Infectious Diseases, 2018, 217, 177-178.	1.9	3
283	Impact of an HPV Education and Vaccination Campaign among Canadian University Students. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 440-446.	0.3	25
284	Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review. Expert Review of Vaccines, 2018, 17, 395-409.	2.0	19
285	Accelerating the Pace of Cancer Prevention- Right Now. Cancer Prevention Research, 2018, 11, 171-184.	0.7	21
286	Perspective: Scientific and ethical concerns pertaining to animal models of autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA). Autoimmunity Reviews, 2018, 17, 435-439.	2.5	14
287	Evaluating Colposcopy with Dynamic Spectral Imaging During Routine Practice at Five Colposcopy Clinics in Wales: Clinical Performance. Gynecologic and Obstetric Investigation, 2018, 83, 234-240.	0.7	11
288	Cervical screening in HPV-vaccinated populations. Climacteric, 2018, 21, 227-234.	1.1	8
289	Response to the comments on â€œRadiofrequency electromagnetic fields and some cancers of unknown etiology: An ecological studyâ€•by J. Gonzalez-Rubio, E. Arribas, R. Ramirez-Vazquez and A. Najera. Science of the Total Environment 599â€“600 (2017) 834â€“843. Science of the Total Environment, 2018, 612, 368-369.	3.9	3
290	Lessons learned from domestic and international human papillomavirus vaccination programs: a review. American Journal of Obstetrics and Gynecology, 2018, 218, 467-473.	0.7	11
291	Chinese medical studentsâ€™ knowledge, attitude and practice towards human papillomavirus vaccination and their intention to recommend the vaccine. Journal of Paediatrics and Child Health, 2018, 54, 302-310.	0.4	28
292	The developing spectrum of gastric-type cervical glandular lesions. Pathology, 2018, 50, 122-133.	0.3	77
293	HPV vaccination. Gynecologic Oncology, 2018, 148, 3-4.	0.6	6
294	Incidence, prevalence, mortality, disability-adjusted life years and risk factors of cancer in Australia and comparison with OECD countries, 1990â€“2015: findings from the Global Burden of Disease Study 2015. Cancer Epidemiology, 2018, 52, 43-54.	0.8	25
295	Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013â€“2016). Papillomavirus Research (Amsterdam, Netherlands), 2018, 6, 77-82.	4.5	14
297	Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14â€“26â€¯year old females in the U.S.. Vaccine, 2018, 36, 7682-7688.	1.7	14
298	Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. American Journal of Preventive Medicine, 2018, 55, 197-204.	1.6	109

#	Article	IF	Citations
299	Genderâ€neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). International Journal of Cancer, 2018, 143, 2299-2310.	2.3	46
300	The challenge of HPV vaccination uptake and opportunities for solutions: Lessons learned from Alabama. Preventive Medicine, 2018, 113, 124-131.	1.6	58
301	Cervical cancer worldwide. Current Problems in Cancer, 2018, 42, 457-465.	1.0	316
302	Human Papillomavirus Vaccines. , 2018, , 430-455.e10.		5
303	The next generation of cervical cancer screening programs: Making the case for risk-based guidelines. Current Problems in Cancer, 2018, 42, 521-526.	1.0	5
304	Cancer immunoprevention: from mice to early clinical trials. BMC Immunology, 2018, 19, 16.	0.9	9
305	A populationâ€based reminder intervention to improve human papillomavirus vaccination rates among adolescents at routine vaccination age. Vaccine, 2018, 36, 4904-4909.	1.7	17
306	Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. The Cochrane Library, 2020, 2020, CD009069.	1.5	288
307	Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine, 2018, 36, 3221-3230.	1.7	43
308	Human Papillomavirus Vaccine Introduction in South Africa: Implementation Lessons From an Evaluation of the National School-Based Vaccination Campaign. Global Health, Science and Practice, 2018, 6, 425-438.	0.6	48
309	Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. The Lancet Child and Adolescent Health, 2018, 2, 707-714.	2.7	44
310	Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017â€“2035: Example from Australia. PLoS ONE, 2018, 13, e0185332.	1.1	52
311	Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008â€“2015. Clinical Infectious Diseases, 2019, 68, 1282-1291.	2.9	40
312	Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus . Infection and Drug Resistance, 2019, Volume 12, 1951-1967.	1.1	47
313	Immunization Campaigns and Strategies against Human Papillomavirus in Italy: The Results of a Survey to Regional and Local Health Units Representatives. BioMed Research International, 2019, 2019, 1-8.	0.9	21
314	Reduction in HPV16/18 prevalence among young women with highâ€grade cervical lesions following the Japanese HPV vaccination program. Cancer Science, 2019, 110, 3811-3820.	1.7	26
315	National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5â€¯years in the United States. International Journal of Pediatric Otorhinolaryngology, 2019, 119, 96-102.	0.4	18
316	The feasibility of universal HPV vaccination program in Shenzhen of China: a health policy analysis. BMC Public Health, 2019, 19, 781.	1.2	13

#	Article	IF	Citations
317	Glandular cell abnormalities in cervical cytology: What has changed in this decade and what has not?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 240, 68-73.	0.5	16
318	Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet, The, 2019, 394, 497-509.	6.3	630
319	Regional variations in human papillomavirus prevalence across time in NHANES (2003â€“2014). Vaccine, 2019, 37, 4040-4046.	1.7	9
320	Matters of fact and politics: Generating expectations of cancer screening. Social Science and Medicine, 2019, 232, 408-416.	1.8	9
321	Human papillomavirus vaccination: The ESGOâ€“EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy. European Journal of Cancer, 2019, 116, 21-26.	1.3	36
322	Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions. Pharmacoeconomics, 2019, 37, 1049-1064.	1.7	7
323	HPV vaccine coverage in Australia and associations with HPV vaccine information exposure among Australian Twitter users. Human Vaccines and Immunotherapeutics, 2019, 15, 1488-1495.	1.4	25
324	HPV infections and cytologic abnormalities in vaccinated women 21â€“34â€¯years of age: Results from the baseline phase of the Onclarity trial. Gynecologic Oncology, 2019, 153, 259-265.	0.6	15
325	HPV Vaccine: Updates and Highlights. Acta Cytologica, 2019, 63, 159-168.	0.7	53
326	Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ: British Medical Journal, 2019, 365, l1161.	2.4	134
327	Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016. International Journal of Cancer, 2019, 145, 2629-2638.	2.3	27
328	Cervical cancer. Lancet, The, 2019, 393, 169-182.	6.3	1,367
329	New prophylactics human papilloma virus (HPV) vaccines against cervical cancer. Journal of Obstetrics and Gynaecology, 2019, 39, 1-10.	0.4	41
330	Is the positive predictive value of highâ€grade cytology in predicting highâ€grade cervical disease falling due to HPV vaccination?. International Journal of Cancer, 2019, 144, 2964-2971.	2.3	14
331	Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Typeâ€“Specific Effectiveness and Evidence of Cross-Protection. Journal of Infectious Diseases, 2019, 219, 382-390.	1.9	50
332	Lifestyle and Cancer Prevention. , 2020, , 337-374.e12.		3
333	Recurrence patterns identify aggressive form of human papillomavirusâ€dependent vulvar cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 231-237.	0.4	1
334	Human papillomavirus types in cervical dysplasia among young HPVâ€vaccinated women: Populationâ€based nested caseâ€“control study. International Journal of Cancer, 2020, 146, 2539-2546.	2.3	15

#	Article	IF	Citations
335	Decision-making about HPV vaccination in parents of boys and girls: A population-based survey in England and Wales. Vaccine, 2020, 38, 1040-1047.	1.7	33
336	Prognosis prediction signature of seven immune genes based on HPV status in cervical cancer. International Immunopharmacology, 2020, 88, 106935.	1.7	0
337	Screening for Cervical Cancer. Medical Clinics of North America, 2020, 104, 1063-1078.	1.1	25
338	Human Papillomavirus Vaccines: An Updated Review. Vaccines, 2020, 8, 391.	2.1	130
339	HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination. Vaccine, 2020, 38, 6304-6311.	1.7	9
340	SIRT2 expression exhibits potential to serve as a biomarker for disease surveillance and prognosis in the management of cervical cancer patients. Medicine (United States), 2020, 99, e18668.	0.4	6
341	Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. Journal of Infectious Diseases, 2020, 222, 948-956.	1.9	29
342	Performance measures for Australian laboratories reporting cervical cytology 2009â€“2017: the impact of the national HPV vaccination program. Pathology, 2020, 52, 522-528.	0.3	1
343	Evaluation of the Burden of HPV-Related Hospitalizations as a Useful Tool to Increase Awareness: 2007â€“2017 Data from the Sicilian Hospital Discharge Records. Vaccines, 2020, 8, 47.	2.1	6
344	Vaccination coverage rates and predictors of HPV vaccination among eligible and non-eligible female adolescents at the Brazilian HPV vaccination public program. BMC Public Health, 2020, 20, 458.	1.2	15
345	Assessing Impact of HPV Vaccination on Cervical Cancer Incidence among Women Aged 15â€“29 Years in the United States, 1999â€“2017: An Ecologic Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 30-37.	1.1	60
346	Surveillance systems for monitoring cervical cancer elimination efforts: Focus on HPV infection, cervical dysplasia, cervical screening and treatment. Preventive Medicine, 2021, 144, 106293.	1.6	10
347	Elimination of cervical cancer in lowâ€•and middleâ€•income countries: Inequality of access and fragile healthcare systems. International Journal of Gynecology and Obstetrics, 2021, 152, 7-11.	1.0	23
348	Projecting the number of new HIV infections to formulate the "Getting to Zero" strategy in Illinois, USA. Mathematical Biosciences and Engineering, 2021, 18, 3922-3938.	1.0	6
349	Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the schoolâ€based human papillomavirus vaccination program. International Journal of Cancer, 2021, 149, 191-199.	2.3	3
350	Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?. Preventive Medicine, 2021, 144, 106321.	1.6	12
351	The role and utility of population-based cancer registries in cervical cancer surveillance and control. Preventive Medicine, 2021, 144, 106237.	1.6	17
352	POLG Gene Variants in Cervical Cancer Patients and Their Associations with Clinical and Pathomorphological Tumor Characteristics. Journal of Clinical Medicine, 2021, 10, 1838.	1.0	2

#	Article	IF	Citations
354	Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. Vaccine, 2021, 39, 2224-2236.	1.7	25
355	Human papillomavirus vaccination coverage and knowledge, perceptions and influencing factors among university students in Guangzhou, China. Human Vaccines and Immunotherapeutics, 2021, 17, 3603-3612.	1.4	18
356	Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data. European Journal of Health Economics, 2021, 22, 1371-1379.	1.4	4
357	Human Papillomavirus and Cervical Cancer. , 0, , .		0
359	Australiaâ€™s Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific. Vaccines, 2021, 9, 921.	2.1	0
360	Epidemiology of HPV Related Malignancies. Seminars in Radiation Oncology, 2021, 31, 286-296.	1.0	21
362	Demographics of Cancer in the Reproductive Age Female. Current Clinical Urology, 2016, , 11-19.	0.0	10
363	Examples of Novel Registered Prophylactic Vaccines, HPV, and JEV. , 2012, , 233-286.		1
364	An ethical framework for public health immunisation programs. NSW Public Health Bulletin, 2012, 23, 111.	0.3	7
365	A School-Based Human Papillomavirus Vaccination Program in Barretos, Brazil: Final Results of a Demonstrative Study. PLoS ONE, 2013, 8, e62647.	1.1	43
366	Genital Human Papillomavirus Infection among Women in Bangladesh: Findings from a Population-Based Survey. PLoS ONE, 2014, 9, e107675.	1.1	29
367	Design of a Highly Effective Therapeutic HPV16 E6/E7-Specific DNA Vaccine: Optimization by Different Ways of Sequence Rearrangements (Shuffling). PLoS ONE, 2014, 9, e113461.	1.1	15
368	Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies. PLoS ONE, 2017, 12, e0171314.	1.1	7
370	Characterizing Twitter Discussions About HPV Vaccines Using Topic Modeling and Community Detection. Journal of Medical Internet Research, 2016, 18, e232.	2.1	138
371	Cervical Cancer Screening in Resource-Constrained Countries: Current Status and Future Directions. Asian Pacific Journal of Cancer Prevention, 2017, 18, 1461-1467.	0.5	31
372	Australian immunisation registers: established foundations and opportunities for improvement. Eurosurveillance, 2012, 17, .	3.9	15
373	Immunisation registers â€“ important for vaccinated individuals, vaccinators and public health. Eurosurveillance, 2012, 17, .	3.9	24
374	The Efficacy and Duration of Vaccine Protection Against Human Papillomavirus. Deutsches Ärzteblatt International, 2014, 111, 584-91.	0.6	39

#	Article	IF	Citations
375	Sexual Behavior in Germany. Deutsches Ärzteblatt International, 2017, 114, 545-550.	0.6	28
376	Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2011â€“2015. Communicable Diseases Intelligence (2018), 0, 43, .	0.3	51
377	Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	6
378	Non-sexual HPV transmission and role of vaccination for a better future (Review). Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	64
379	HPV Vaccine in Adolescents. Pediatric Annals, 2019, 48, e71-e77.	0.3	5
380	Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs. South Asian Journal of Cancer, 2013, 02, 187-192.	0.2	33
381	Human papillomavirus research on the prevention, diagnosis, and prognosis of cervical cancer in Taiwan. Biomedical Journal, 2012, 35, 297.	1.4	6
382	Cervical HPV Infection in Indian Women: Screening and Immunization as Preventive Strategies. MGM Journal of Medical Sciences, 2014, 1, 65-75.	0.1	1
383	Does the Success of a School-based HPV Vaccine Programme Depend on Teachers' Knowledge and Religion? - a Survey in a Multicultural Society. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4651-4654.	0.5	15
384	Should Male Circumcision be Advocated for Genital Cancer Prevention?. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4839-4842.	0.5	21
385	A Systematic Review of Cervical Cancer Incidence and Mortality in the Pacific Region. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9433-9437.	0.5	27
386	Vaccine Misconceptions and Low HPV Vaccination Take-up Rates in Singapore. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5119-5124.	0.5	17
387	Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy. Scientific Reports, 2021, 11, 20083.	1.6	3
390	Bug Breakfast in the Bulletin: The early impact of the National HPV Vaccination Program. NSW Public Health Bulletin, 2012, 23, 208.	0.3	0
391	Routine Adult Vaccines and Boosters. , 2013, , 77-86.		1
392	Sexuell Ã¼bertragene Infektionen (STI). Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 546-559.	0.0	0
394	Topics in Cervical Cancer Screening and HPV Vaccination. Health Evaluation and Promotion, 2014, 41, 322-331.	0.0	1
395	REGIONAL VACCINATION PROGRAM FOR THE PREVENTION OF HPV-ASSOCIATED DISEASES IN THE KHMAO-YUGRA. Russian Journal of Infection and Immunity, 2014, 4, 155.	0.2	0

#	Article	IF	Citations
396	Squamous Cell Carcinoma of the Anal Canal. , 2015, , 513-535.		0
397	Dermatologie und Venerologie. , 2015, , 293-307.		0
398	Human Papillomaviruses. , 2015, , 15-43.		0
399	Papillomaviruses. , 2015, , 1794-1806.e4.		2
400	Results of vaccination against HPV-related diseases and cervical cancer in the Moscow Region. Russian Bulletin of Obstetrician-Gynecologist, 2015, 15, 9.	0.0	5
401	InterdisziplinÃres und sektorenÃ¼bergreifendes Management am Beispiel der Implementierung einer freiwilligen HPV-Schulimpfung. , 2017, , 137-144.		0
402	Crossroads of Primary and Secondary Cervical Cancer Prevention Strategies in Resource-Constrained Settings. Journal of Cancer Prevention & Current Research, 2017, 7, .	0.1	0
403	Cervical cancer prevention through vaccination in 2019. Medic Ro, 2019, 2, 36.	0.0	0
404	Sexually Transmitted Infections and Sexual Healthcare of Homeless and Street-Involved Youth. , 2020, , 243-270.		1
405	Adolescent Girlsâ€™ Preferences for HPV Vaccines: A Discrete Choice Experiment. Advances in Health Economics and Health Services Research, 2014, , 93-121.	0.2	0
406	Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources. Expert Review of Vaccines, 2022, 21, 227-240.	2.0	6
407	HPV-Impfung: Sehr effektiv â€“ aber immer noch vernachlÃssigt. , 0, , .		0
409	Long-Term Effects of Human Papillomavirus Vaccination in Clinical Trials and Real-World Data: A Systematic Review. Vaccines, 2022, 10, 256.	2.1	4
410	What do we know about cervical cancer and HPV vaccines? A cross-sectional questionnaire evaluated by midwives and nurses. Journal of Surgery and Medicine, 2022, 6, 295-299.	0.0	0
411	Measuring school level attributable risk to support school-based HPV vaccination programs. BMC Public Health, 2022, 22, 822.	1.2	6
412	Knowledge and attitude regarding cervical cancer and its prevention among young female adults in Kuantan, Malaysia. Journal of Education and Health Promotion, 2021, 10, 332.	0.3	1
413	Benefits of HPV vaccination. Medic Ro, 2022, 2, 44.	0.0	0
414	Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer. Frontiers in Oncology, 2022, 12, .	1.3	1

#	Article	IF	Citations
415	Increased detection of high grade CIN, when using Electrical Impedance Spectroscopy as an adjunct to routine colposcopy, is maintained when used across international boundaries: Prospective data from nine European countries. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, , .	0.5	3
416	Attitude and hesitancy of human papillomavirus vaccine among Saudi parents. Journal of Family Medicine and Primary Care, 2022, 11, 2909.	0.3	10
417	HPV Vaccination in Young Males: A Glimpse of Coverage, Parental Attitude and Need of Additional Information from Lombardy Region, Italy. International Journal of Environmental Research and Public Health, 2022, 19, 7763.	1.2	2
418	Implementation of HPV vaccine worldwide and in Japan. The Journal of the Japanese Society of Clinical Cytology, 2022, 61, 227-237.	0.0	0
419	Provision of cervical screening for transmasculine patients: a review of clinical and programmatic guidelines. BMJ Sexual and Reproductive Health, 2023, 49, 118-128.	0.9	0
420	Primary prevention of cervical cancer in women: Human papillomavirus vaccine. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2023, 281, 29-31.	0.5	0
421	HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis. BMC Cancer, 2022, 22, .	1.1	2
422	The importance of long-term follow up of participants in clinical trials. British Journal of Cancer, 2023, 128, 432-438.	2.9	6
423	Cervical Cancer Treatment and HPV Vaccination. Journal of the Nihon University Medical Association, 2022, 81, 325-328.	0.0	0
424	Human papillomavirus: What we know and what we doing?. Archives of Community Medicine and Public Health, 2023, 9, 004-010.	0.1	0
425	HPV Vaccination. , 2023, , 209-219.		0
427	HPV-Impfung. , 2023, , 219-231.		0
428	Human Papillomavirus Vaccines. , 2023, , 484-513.e11.		0
433	Mechanisms of chemotherapy resistance in cervical cancer. , 2024, , 53-70.		0